Developing
a pipeline
of first-in-class NAMPT inhibitors
Developing the first well-tolerated NAMPT inhibitor unlocks the potential of NAMPT as a drug target, with treatment opportunities across more than 20 diseases in which NAMPT is dysregulated.
Developing a pipeline of first-in-class NAMPT inhibitors
Developing the first well-tolerated NAMPT inhibitor unlocks the potential of NAMPT as a drug target, with treatment opportunities across more than 20 diseases where NAMPT is dysregulated.
Developing the first well-tolerated NAMPT inhibitor unlocks the potential of NAMPT as a drug target, with treatment opportunities across more than 20 diseases where NAMPT is dysregulated.
Developing a pipeline
of first-in-class NAMPT inhibitors
Developing a pipeline of first-in-class NAMPT inhibitors
Developing the first well-tolerated NAMPT inhibitor unlocks the potential of NAMPT as a drug target, with treatment opportunities across more than 20 diseases where NAMPT is dysregulated.
Remedy Plan pipeline
We are advancing a pipeline of novel, hyperbolic NAMPT inhibitors, starting in oncology.
RPT1G, our lead asset, is in a Phase 1 trial (NCT#07107126) in patients with relapsed/refractory AML and higher-risk MDS. Our goal is to scale this drug pipeline to reach more patients suffering with solid tumor cancers, autoimmune disorders, and more.
Interested in exploring a collaboration?
Contact us at [email protected]
Academic Collaborations
Remedy Plan collaborates with leading academic institutions to explore the potential of our pipeline of unique NAMPT inhibitors.
Collab 1
Maecenas nunc enim, vehicula non orci a, tempus sollicitudin massa. Morbi cursus nisl id cursus aliquet. Phasellus aliquet diam a consectetur facilisis.
Select Publications
Our research and progress has been featured at some of the most respected industry events, including the American Society of Hematology Annual Meeting, the American Association for Cancer Research Annual Meeting, and the American Society of Clinical Oncology Annual Meeting.